Indian drug shares declined Wednesday following US President Trump’s tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India’s vital role in supplying affordable medicines to the US.
How Bessent, America’s bond salesman, cornered Japan on big spending
In a significant dialogue, US Treasury Secretary Bessent encouraged Japan to implement reforms in its fiscal and monetary policies. Aiming to stabilize the yen and
September 18, 2026